Dermatology Department, Catholic University of the Sacred Heart, Rome, Italy.
Int J Immunopathol Pharmacol. 2009 Oct-Dec;22(4):961-6. doi: 10.1177/039463200902200411.
Psoriasis is a chronic inflammatory skin condition characterized by inflammatory dermal infiltrate and hyperproliferative keratinocytes. The pathogenesis of this disease is mediated by a dysregulation of the innate immunity and cytokine production. Tumor necrosis factor alpha (TNFalpha) is considered the most important cytokine involved in the pathological mechanism of psoriasis. Recently, several therapies have been introduced for the treatment of psoriasis that try to block TNF alpha activity. Among these treatments etanercept is a fusion protein that specifically targets TNF alpha. We performed a study on twelve psoriatic patients aimed at evaluating the effect of etanercept treatment on the production and expression of TNFalpha and its receptors, in lesional and uninvolved psoriatic skin. We demonstrated that after three month of etanercept treatment at 50 mg/wk, TNF, TNF-RI and TNF-RII immunostaining in lesional and non-lesional skin samples of patients was greatly reduced, suggesting that this treatment not only acts on stable lesional plaques, but also at a very early stage of the disease.
银屑病是一种慢性炎症性皮肤病，其特征为炎症性真皮浸润和过度增殖的角质形成细胞。这种疾病的发病机制是由先天免疫和细胞因子产生的失调所介导的。肿瘤坏死因子-α（TNFα）被认为是参与银屑病病理机制的最重要的细胞因子之一。最近，已经引入了几种治疗银屑病的方法，试图阻断 TNFα 的活性。其中，依那西普是一种针对 TNFα 的融合蛋白。我们对 12 例银屑病患者进行了一项研究，旨在评估依那西普治疗对病变和非病变银屑病皮肤中 TNFα 及其受体产生和表达的影响。我们证明，在每周 50mg 的依那西普治疗 3 个月后，患者病变和非病变皮肤样本中的 TNF、TNF-RI 和 TNF-RII 免疫染色大大减少，表明这种治疗不仅作用于稳定的病变斑块，而且还作用于疾病的早期阶段。
